Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7132995 | 1.00 | PDE4A (0.61) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL28066668 | 1.00 | PDE4A (0.61) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL6234202 | 0.98 | PDE4A (0.59) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL9576619 | 0.98 | PDE4A (0.59) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL15453928 | 0.93 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL1129690 | 0.93 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL8218436 | 0.93 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL14124935 | 0.84 | PDE4A (0.44) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL27216229 | 0.84 | PDE4A (0.44) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL1635580 | 0.83 | LMNA (0.59) | PDE4ALMNAL3MBTL1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116139336-B | Multichannel biological scaffold and preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-09-10 | — | — | CN | claimed |
| CN-113893219-B | Drug-loaded nano micelle, preparation method, application and method for preparing planting base station based on drug-loaded nano micelle | 中国人民解放军空军军医大学 | 2023-06-23 | — | — | CN | claimed |
| US-20230191003-A1 | COMPOSITE SCAFFOLD MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Novovita Bio-products Co., Ltd. (CN) | 2023-06-22 | — | — | US | claimed |
| CN-116139336-A | Multichannel biological scaffold and preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2023-05-23 | — | — | CN | claimed |
| US-20230118503-A1 | NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS FOR PROPHYLAXIS AND TREATMENT OF EYE DISEASES | TURSKI CHRISTOPHER (US) | 2023-04-20 | — | — | US | claimed |
| US-20230095764-A1 | NOVEL KETOGENIC COMPOUNDS, COMPOSITIONS, METHODS AND USE THEREOF | KETOFIBE (9211-3133 QUEBEC INC.) (CA) | 2023-03-30 | — | — | US | claimed |
| CN-115120562-A | Drug-loaded nanofiber scaffold particle and preparation method and application thereof | 苏州博创同康生物工程有限公司 | 2022-09-30 | — | — | CN | claimed |
| CN-113893219-A | Drug-loaded nano micelle, preparation method thereof, application of drug-loaded nano micelle in preparation of implant abutment and method for preparing implant abutment based on drug-loaded nano micelle | 中国人民解放军空军军医大学 | 2022-01-07 | — | — | CN | claimed |
| US-20210275475-A1 | NOVEL KETOGENIC COMPOUNDS, COMPOSITIONS, METHODS AND USE THEREOF | 9500-0535 QUEBEC INC. (CA) | 2021-09-09 | — | — | US | claimed |
| EP-3806906-A1 | NOVEL KETOGENIC COMPOUNDS, COMPOSITIONS, METHODS AND USE THEREOF | Ketofibe (9211-3133 Quebec Inc.) (CA) | 2021-04-21 | — | — | EP | claimed |
| CN-103432087-B | Clindamycin hydrochloride preparation for injection and preparation method thereof | WUHAN PUSHENG PHARMACEUTICAL CO LTD | 2015-02-18 | — | — | CN | claimed |
| CN-104103820-A | Spherical porous channel graphite negative electrode material of lithium ion battery and preparation method thereof | PETER WAN | 2014-10-15 | — | — | CN | claimed |
| CN-103880138-A | High-efficiency flocculating agent for waste water treatment | SHANGHAI HESHUN CHEMICAL TECHNOLOGY CO LTD | 2014-06-25 | — | — | CN | claimed |
| CN-103432087-A | Clindamycin hydrochloride preparation for injection and preparation method thereof | WUHAN PUSHENG PHARMACEUTICAL CO LTD | 2013-12-11 | — | — | CN | claimed |
| CN-103417514-A | Microencapsulated butylphthalide medicine composition, preparation method and applications | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD | 2013-12-04 | — | — | CN | claimed |
| CN-102709566-A | Spherical silicon carbon composite anode material of lithium ion battery and preparation method for spherical silicon carbon composite anode material | LIXIN QINGDAO NEW ENERGY MATERIALS CO LTD | 2012-10-03 | — | — | CN | claimed |
| US-20100009007-A1 | Non-covalent modification of microparticles and process of preparing same | BAXTER INTERNATIONAL INC. (US) | 2010-01-14 | — | — | US | claimed |
| WO-2010006194-A2 | NON-COVALENT MODIFICATION OF MICROPARTICLES AND PROCESS OF PREPARING SAME | BAXTER INTERNATIONAL INC. (US) | 2010-01-14 | — | — | WO | claimed |
| CN-1692910-A | Oral prepn. of disodium adenosine triphosphate | SUN MINGJIE (CN) | 2005-11-09 | — | — | CN | claimed |
| US-4649050-A | Electrolyte solutions containing polyanionic materials | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1987-03-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230095764-A1 | NOVEL KETOGENIC COMPOUNDS, COMPOSITIONS, METHODS AND USE THEREOF | PC, LRBA, BCKDK | PDE4A 2451/4885LMNA 2310/4885L3MBTL1 1517/4885 |
| US-20100009007-A1 | Non-covalent modification of microparticles and process of preparing same | CHMP4B, PHOSPHO1, PLTP | PDE4A 2106/4885LMNA 1772/4885L3MBTL1 3882/4885 |
| US-20230118503-A1 | NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS FOR PROPHYLAXIS AND TREATMENT OF EYE DISEASES | MME, ECE1, ENPEP | PDE4A 871/4885LMNA 535/4885L3MBTL1 4720/4885 |
| US-20210275475-A1 | NOVEL KETOGENIC COMPOUNDS, COMPOSITIONS, METHODS AND USE THEREOF | PC, LRBA, GPR119 | PDE4A 2464/4885LMNA 2248/4885L3MBTL1 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.